IQVIA Holdings is riding a fifth consecutive quarter of accelerating top-line momentum, with revenue growth reaching 8.0% year-over-year in Q3 2026 versus just 2.3% in Q3 2024, driven by stronger clinical trial and data analytics demand.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has reaccelerated to 8.0% year-over-year in Q3 2026 on a quarterly base that expanded from $3.8B to $4.4B, but this momentum has coincided with 160 basis points of gross margin erosion (35.4% to 33.8%) and an operating margin shift from 14-15% down to 12-13%, cushioned only partially by SG&A discipline at 11-13% of revenue, while stock-based compensation has nearly doubled to $83M per quarter and the Q4 2025 divergence between $292M of gross profit and $732M of operating income warrants further investigation.
IQVIA accelerates innovation and improves patient outcomes through its advanced analytics and technology, helping life sciences organizations bring treatments to market faster.
The company has a wide moat, indicating strong competitive advantages and barriers to entry in its market.
Top holder Vanguard Group owns 11.4% of IQVIA, reflecting confidence from major institutional investors.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 27, 2026 | $3.34+2.5% vs $3.26 | $4.4B+1.4% vs $4.4B |
Q3 2026 Jul 28, 2026 | $3.15+4.0% vs $3.03 | $4.4B+1.5% vs $4.3B |
Q2 2026 May 5, 2026 | $2.90+2.8% vs $2.82 | $4.2B+1.2% vs $4.1B |
Q1 2026 Feb 5, 2026 | $3.42+0.6% vs $3.40 | $4.4B+2.9% vs $4.2B |
US government debt-to-GDP exceeds 120%, while annual interest payments now surpass the budget for national defense. Our three best-performing stocks this quarter were Meta, IQVIA and Shell. Our three largest detractors this quarter were Danone, Heidelberg and Samsung Electronics.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Citizens Financial Group Inc. RI increased its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 67.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,251 shares of the medical research company's stock after buying
IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.
Benchmark IQV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for IQVIA Holdings Inc. (IQV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — | |
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — | |
| $204.74 | $15.68B | 35.32 | -0.37% | 5.45% | 4.85% | — | |
| $653.11 | $18.23B | 35.78 | 19.97% | 18.24% | 99.76% | — | |
| $303.73 | $49.34B | 49.40 | 16.34% | 29.34% | 14% | — | |
| $119.65 | $24.25B | 60.28 | 21.22% | 6.71% | 7.11% | — |
IQVIA Holdings Inc. (IQV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
IQVIA Holdings Inc. (IQV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 27, 2026·SEC
Jul 28, 2026·SEC
Jun 11, 2026·SEC
Get notified when IQV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IQVIA Holdings Inc. (IQV) stock FAQ — growth, dividends, profitability & financials explained
IQVIA Holdings Inc. (IQV) reported $17.31B in revenue over the trailing twelve months. Revenue was $16.31B in fiscal year 2025. That is 277% more than the $4.33B of fiscal year 2011.
IQVIA Holdings Inc. (IQV) grew revenue by 8.8% over the trailing twelve months, compared with the twelve months before.
Yes. IQVIA Holdings Inc. (IQV) earned $1.39B in net income over the trailing twelve months (a 8.1% net margin).
IQVIA Holdings Inc. (IQV) had a return on equity (ROE) of 21.4% over the trailing twelve months. That is well above the market's typical 10-15%.
IQVIA Holdings Inc. (IQV) generated $2.08B in free cash flow over the trailing twelve months.
